- Home
- BRNS vs KZR Comparison
BRNS vs KZR Comparison
Compare BRNS & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- KZR
- Stock Information
- Founded
- BRNS 2016
- KZR 2015
- Country
- BRNS United Kingdom
- KZR United States
- Employees
- BRNS N/A
- KZR N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- KZR Health Care
- Exchange
- BRNS Nasdaq
- KZR Nasdaq
- Market Cap
- BRNS 41.0M
- KZR 46.5M
- IPO Year
- BRNS 2021
- KZR 2018
- Fundamental
- Price
- BRNS $1.04
- KZR $6.19
- Analyst Decision
- BRNS Strong Buy
- KZR Hold
- Analyst Count
- BRNS 2
- KZR 2
- Target Price
- BRNS $3.00
- KZR $9.00
- AVG Volume (30 Days)
- BRNS 46.0K
- KZR 48.3K
- Earning Date
- BRNS 11-06-2024
- KZR 03-13-2025
- Dividend Yield
- BRNS N/A
- KZR N/A
- EPS Growth
- BRNS N/A
- KZR N/A
- EPS
- BRNS N/A
- KZR N/A
- Revenue
- BRNS $14,969,000.00
- KZR N/A
- Revenue This Year
- BRNS $1,805.74
- KZR N/A
- Revenue Next Year
- BRNS N/A
- KZR N/A
- P/E Ratio
- BRNS N/A
- KZR N/A
- Revenue Growth
- BRNS 106.21
- KZR N/A
- 52 Week Low
- BRNS $0.80
- KZR $5.20
- 52 Week High
- BRNS $4.16
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- BRNS 48.42
- KZR 38.28
- Support Level
- BRNS $0.91
- KZR $6.15
- Resistance Level
- BRNS $1.15
- KZR $6.50
- Average True Range (ATR)
- BRNS 0.15
- KZR 0.29
- MACD
- BRNS -0.01
- KZR -0.02
- Stochastic Oscillator
- BRNS 34.96
- KZR 5.13
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.